Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
CVKD Stock Chart & Stats
$12.92
-$1.27(-7.12%)
At close: 4:00 PM EST
$12.92
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$4.91 - $20.39
Previous CloseN/A
Volume16.20K
Average Volume (3M)53.02K
Market Cap
$19.36M
Enterprise Value$15.50M
Total Cash (Recent Filing)$3.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 18, 2026EPS Estimate
-1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding2,338,127
10 Day Avg. Volume76,200
30 Day Avg. Volume53,023
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.38
Price to Sales (P/S)0.00
P/FCF Ratio-2.40
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.62K
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$45.00Price Target Upside248.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Expansion (VLX-1005)The VLX-1005 acquisition materially broadens Cadrenal’s pipeline into HIT with Orphan Drug and Fast Track designations, which can shorten development timelines and extend exclusivity. This first-in-class asset diversifies clinical risk and creates a durable commercial opportunity within the large anticoagulation market.
Strengthened Clinical GovernanceAdding an experienced clinical-development director improves trial design, regulatory strategy and execution oversight. Durable governance expertise reduces execution risk across multi-year development programs, enhances credibility with regulators and partners, and increases probability of efficient advancement to pivotal studies.
Low Financial LeverageZero reported debt provides structural financial flexibility, lowering fixed obligations and bankruptcy risk. This debt capacity supports strategic options (partnering, milestone payments) and preserves cash flow for R&D, enabling management to prioritize clinical progress without immediate debt service constraints.
Bears Say
Persistent Cash BurnSustained, rising negative operating cash flow indicates structural funding pressure. Continued cash burn requires recurring external financing or partnerships, raising dilution and execution risk; without secured multi-quarter runway, multi-year clinical programs could face delays or scope reductions.
Pre-revenue With Widening LossesLack of operating revenue and widening net losses mean the business depends on capital markets to sustain R&D. This structural absence of cash-generating operations lengthens time to self-sufficiency, constrains strategic flexibility, and elevates the consequences of clinical or regulatory setbacks on long-term viability.
Reliance On Equity FinancingRepeated use of ATM programs and direct registered offerings shows ongoing dependence on equity to fund operations. This durable financing pattern increases dilution risk, may limit long-term shareholder returns, and can weaken negotiating leverage with partners or licensors when capital is consistently raised via equity.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $4.91 and its highest was $20.39 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $19.36M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 9 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$1.31 earnings per share for the quarter, beating the consensus estimate of -$1.55 by $0.24.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.17.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,338,127 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.31 in its last earnings report, beating expectations of -$1.55. Following the earnings report the stock price went down -3.13%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$45.00
▲(248.30% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
16.94% Insiders
2.36% Mutual Funds
1.08% Other Institutional Investors
77.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---